SHILPAMEDNSE13 November 2025

Shilpa Medicare Limited has informed the Exchange about Investor Presentation

Shilpa Medicare Limited

Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739

Date: 13 November, 2025

To Corporate Relationship Department BSE Limited, 1st Floor, Rotunda Building, P.J. Towers, Dalal Street, Mumbai – 400 001.

To National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No.C/1, G Block Bandra Kurla Complex, Bandra (E) Mumbai – 400 051.

Scrip Code: BSE - 530549/ Stock Symbol: NSE – SHILPAMED

Dear Sir/Madam,

Sub: Investor Presentation of the Company for the quarter ended 30 September 2025 Ref: Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

reference

the quarter With ended 30 September, 2025 on Company overview, Business highlights, Financial performance and other updates is enclosed herewith for your consideration.

the captioned subject,

Investor Presentation

the

for

We request you to take the same on record.

A copy of this intimation is also being made available at:

https://vbshilpa.com/investor-presentation.php

Thanking you

For Shilpa Medicare Limited,

Ritu Tiwary Company Secretary & Compliance Officer

Shilpa Medicare Ltd 2Q & 1H FY26 Earnings Presentation

Date: 13th November 2025

Safe Harbour

Certain statements in this document may be forward - looking statements. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Shilpa Medicare Limited (SML) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

Shilpa Medicare at a glance

Established in 1987, we have 35+ years track record

Existing Business Segments: API , Formulation, CDMO, Biologics

Emerging Businesses: NDDS, ADC and Recombinant Human Albumin

10+ Regulatory approved manufacturing + R&D facilities (incl Analytical Lab)

400+ R&D Personnel

500+ Regulatory Filings across the world

Worldwide presence in 50+ countries

1H FY26 Financials

Revenue INR 700 crores (+8% YoY) EBITDA INR 208 crores (+20% YoY)

Key operating verticals

API

Formulations

Biologics

1HFY26 Revenue contribution

56%

37%

Legal Entities

Areas of Operation

▪ Shilpa Pharma Lifesciences

▪ Oncology ▪ Non-Oncology ▪ Payloads and Linkers ▪ Peptides ▪ Polymers ▪ CDMO

▪ Shilpa Medicare ▪ Shilpa Therapeutics ▪ FTF Pharma

▪ Tablets/Capsules ▪ Injectables ▪ Oral Dissolving Films ▪ Transdermal patches ▪ CDMO

▪ Shilpa Biologicals ▪ Shilpa Biocare

▪ NBE ▪ Microbials Products ▪ Mammalian Products ▪ GLP-1 ▪ CDMO ▪ ADCs

API Includes others

Management Commentary

I am pleased to report another quarter of strong performance, building on the positive momentum from 1QFY26. The quarter saw revenue growth of 7%, with highest quarterly revenue and EBITDA, having robust EBITDA margins of ~30%. Our results reflect the successful execution of our strategy across various divisions.

In our Formulations business, our key 505(b)(2) assets continue to gain US market share through our partner, validating our complex development capabilities and differentiated approach to drive steady growth. Domestically, we are geared up to launch NorUDCA in 3QFY26, a novel first-in-class therapy for a large addressable NAFLD market in India. We have strategically partnered with three leading Indian companies for its marketing, along with launching the brand under our own label, ensuring robust market penetration. We also successfully completed Phase 3 trials for Ondansetron Extended-Release Injection a Novel Once-Weekly for Chemotherapy-Induced Nausea and Vomiting (CINV)

Our API segment is firmly back on a growth track, led by the commercialization of our expanded capacities of key products, underscoring our commitment to strengthening this core business.

Our Biologics division is accelerating innovation, with key NBEs advancing towards Phase 1 trials in FY27 and major biosimilars progressing in clinical development.

Looking ahead, our outlook remains optimistic, with clear focus on building on a solid foundation marked by innovation and strategic expansion, designed to deliver sustainable and profitable growth.

— Mr. Vishnukant Bhutada Managing Director

2Q & 1H FY26 Financial Performance

2Q FY26 – Financial Highlights Highest Quarterly Revenue and EBITDA

2Q FY26 (Consolidated)

Particulars (INR cr)

2QFY26

2QFY25

Total Revenue

Gross Profit

GP Margin

EBITDA

EBITDA Margin

PAT

PAT Margin

372

266

72%

110

30%

12%

349

227

65%

26%

Revenue Break-up (INR crs)

YoY

17%

700 bps

21%

400bps

144%

700bps

1QFY26

328

248

76%

30%

14%

QoQ

13%

(400)Bps

Formulation, 139.0

12%

(6)%

(200)bps

Biologicals, 25.0

Others, 3.0

2Q FY26

37%

#API, 205.0

55%

Result commentary ▪ Highest quarterly revenue at INR 372crs, grew by 7% on YoY basis; driven by growth in our API and FDF verticals ▪ Highest quarterly EBITDA at INR 110crs growing 21% YoY with EBITDA Margins expanding to 30%

All numbers are rounded off to nearest one

1H FY26 – Financial Performance

1H FY26 (Consolidated)

Revenue Break-up (INR in cr.)

Particulars (INR cr)

1HFY26

1HFY25

YoY (%)

Total Revenue

Gross Profit

GP Margin

EBITDA

EBITDA Margin

PAT

PAT Margin

700

514

74%

208

30%

13%

651

436

67%

174

27%

18%

700bps

20%

300bps

184%

800bps

Biologicals, 61.0

Others, 9.0

1HFY26

Formulation, 238.0

34%

API, 392.0

56%

Revenue growth came in at 8% on YoY basis

Result commentary ▪ ▪ Gross margins expanded to 74%, driven by better product mix ▪ ▪

EBITDA came in at INR 208crs, with EBITDA Margins expanding to ~30% PAT of INR 91crs in 1HFY26 surpasses full year FY25 PAT of INR 78crs

All numbers are rounded off to nearest one

Consolidated Performance

Revenues

EBITDA and Margins

349

328

372

651

700

30%

26%

110

27%

174

(INR in Cr.)

30%

208

2QFY25

1QFY26

2QFY26

1HFY25

1HFY26

2QFY25

1QFY26

2QFY26

1HFY25

1HFY26

PBT and Margins

15%

11%

17%

10%

16%

114

PAT and Margins

14%

12%

13%

2QFY25

1QFY26

2QFY26

1HFY25

1HFY26

2QFY25

1QFY26

2QFY26

1HFY25

1HFY26

Financial Summary

Adjusted ROCE^

Gross Block (INR crs)

15.3%

17.2%

10.3%

11.3%

4.2%

1,538

1,587

1,670

1,991

2,049

FY22

FY23

FY24

FY25

1HFY26*

FY22

FY23

FY24

FY25

1HFY26

Net Debt to EBITDA (x)

6.7

5.8

Net Capex (INR crs)

1.6

1.4

331

225

172

216

153

FY22

FY23

FY24

FY25

1HFY26*

FY22

FY23

FY24

FY25

1HFY26

^ Adjusted ROCE excluding investments made in potential high growth biologics & NBE business Note: 1HFY26 numbers are on TTM basis*

API Business

API – Growth driven by core portfolio

Incl. Captive

225

226

16 7

112

117

256

18 7

141

404

158

202

481

34 14

176

257

Oncology

Non-Oncology

CDMO

Others

Oncology Non-Oncology

CDMO Others

2QFY25

1QFY26

2QFY26

1HFY25

1HFY26

▪

(INR in Cr.)

Revenue growth was at ~14% YoY for the quarter and ~19% for 1HFY26 YoY

Ex-CDMO API portfolio growth was at ~21% YoY for the quarter. Growth in API segment was led by both Onco and Non-Onco portfolio with large contribution from key base business products

Commercialization of expanded capacities resulted in improved utilizations

▪ Maintaining steady commercial

supply and recurring revenue from our flagship Polymer contract, which commenced 1Q FY26

▪ Developing multiple complex APIs

and Specialty products

API – Ongoing Developments

API Molecules

CDMO

Polymer and Peptide

▪ Commissioned expanded capacities of high- Demand Products – UDCA, Tranexamic Acid, and other key Onco molecules

▪ Sustained growth driven by new product

introductions, optimized production scale, and strong captive demand

▪ Completed validation for 2 new products

▪ Initiated validation for 1 new project

▪ Initiated de-bottlenecking in various blocks

▪ 1 program received US FDA approval, expected to commercialize

in FY26

▪ 1 program expected to commercialize in FY27, NDA filed

▪ Added 3 new customers, including a big pharma

▪ As a CDMO in NDA program, partner obtained Phase 2 clearance

for new indication with fast-track status

▪ New dedicated block for OLC expected to be commercialized in

FY26

▪ 25+ programs are ongoing in different phases of development for

our clients

▪ Commercial supplies continues of large polymer project worth ~USD 4mn received from a MNC for non pharma applications

▪ Successfully completed proof-of-concept for an ophthalmic

polymer in collaboration with a global customer

▪ Delivered key polymer to a leading pharma company for

advanced, targeted drug delivery systems

▪ New Peptide project - Supplied initial quantities to a MNC

▪ GLP 1 - Liraglutide DMF readied and Semaglutide – validation to be completed in 2HFY26 with filing expected in 1HFY27

API – DMF Filings

USFDA

EU/EMEA

GCC & ROW

MFDS

Canada

Australia

China

PMDA Japan

Russia

Brazil

New product introduction and increase in geographical coverage replicated with 269 DMF filings with major regulatory authorities Unit 1 successfully completed ANVISA (Brazil) and COFEPRIS (Mexico) regulatory audits – GMP Certificate received 23 New DMFs filed across markets in 1HFY26

Formulations Business

Novel product – First‐in‐class treatment for NAFLD

▪

First‐in‐class treatment for Non‐alcoholic Fatty Liver Disease (NAFLD) in India

First company globally to obtain approval for NorUDCA in NAFLD indication

▪ NAFLD is currently the most prevalent liver condition globally, affecting about 25% of the

world’s population (approximately 1.2 billion people) and impacting an estimated 188 million

individuals in India alone

▪ NorUDCA demonstrates significant improvement in both liver structure and function,

confirming NorUDCA’s superior efficacy, an excellent safety profile with no major adverse

events reported compared to placebo in NAFLD

▪

Strategic partnership with 3 large companies for marketing in India, to ensure robust

market penetration

▪

Shilpa will also launch NorUDCA under its own brand – NoducaTM

▪ Established a dedicated, specialized MR team to drive market penetration

▪ Applying for additional indication of NASH in global trials

*CDMO revenue is a part of respective divisions

Novel product launch to drive meaningful growth

120

139

223

119

238

Europe

RoW Domestic

Licensing/ Services

Europe

RoW Domestic

Licensing/Services

2QFY25

1QFY26

2QFY26

1HFY25

1HFY26

3 complex/505(b)(2) projects commercialized 5 complex/505(b)(2) projects under various stages of development

(INR in Cr.)

▪

Revenue from FDF segment reported a healthy growth ~16% YoY

Ex-Licensing income, base business reported robust revenue growth of ~60% in the quarter (YoY) and ~67% in 1HFY26 YoY

The growing U.S. market share for Pemetrexed and Bortezomib drives higher US revenue

▪ All 3 approved and launched NDAs

have limited competition. More NDAs will be filed in coming quarters

▪ Gearing up for launch of NorUDCA in

3QFY26, India’s first‐in‐class therapy for NAFLD. Strategic partnership with 3 large companies for marketing in India

▪

Formed a JV with PPI and Koanna, a wholly-owned subsidiary of Shilpa Medicare

Received recommendation for grant of the final Marketing Authorization of Rivaroxaban ODF, commercialization expected in FY27

FDF – Update on complex pipeline

SMLNUD07 NorUDCA

SMLTDP08 Rotigotine

SMLTOP09

SMLODF010 Tadalafil Film

SMLINJ011 Ondansetron ER

SMLTDP012

SMLOSD014

▪ Received landmark

▪ Transdermal Patch for

treatment of Parkinson’s disease ▪ Europe submission completed by our partner

▪ US bioequivalence studies were successful. Preparing our Marketing Application for submission

approval for NorUDCA, India’s first‐in‐class therapy for NAFLD—making Shilpa the first company globally to obtain approval for NAFLD.

▪ To Launch NorUDCA tablets in India in 3QFY26, while advancing global regulatory efforts to bring vital therapy to patients internationally

▪ Topical lotion for treatment of Androgenic Alopecia

▪ Phase 2 concluded

with data submitted to Indian regulators - Phase 3 to commence upon receiving authorization ▪ EU regulators

validated our clinical development approach through Scientific Advice, significantly de-risking our regulatory pathway

▪ First company to

▪ A Novel Long-Acting

secure EU approval for multiple strengths of tadalafil films under hybrid application

Injection for prevention of Acute and Delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, radiotherapy and other associated medication. Market Size is ~USD 375 mn (Global)*

▪ Positive Phase 3

results in India with launch planned in early 2026 ▪ Global clinical

development has been initiated for approval and launch of product in US, Europe and ROW

▪ An innovative delivery platform offering enhanced compliance and steady plasma levels for Alzheimer’s patients

▪ A unique patient-

friendly formulation enabling early market access in underserved anticoagulation segments

▪ A once-weekly

▪ Targeting earlier

transdermal patch delivery system enhancing patient adherence, compliance and convenience

▪ Preliminary clinical trials initiated; full development to be completed by end of FY26

market access in the US market compared to the conventional formulation

▪ Targeting a ~USD 10+ bn U.S. branded market with our enhanced delivery platform

▪ Exhibit batches

completed and BE Studies planned

*Source: IQVIA – MAT-June 25 Note: Our project numbering does not include #13

Filings – Formulations

Formulations – Regulatory Filings

Pending

Approved

US ANDA and NDA

Canada

Robust regulatory filings to strengthen the base for growth in the formulation segment 36 new approvals were received in 1HFY26

656

315

341

ROW

Biologics & NBE

Biologics – Growth envisioned on 4 pillars

Biologics

Novel Biologics

Integrated CDMO @Dharwad

ADC Platform

▪ Five active Novel Biologic Entity (NBE) programs advancing for multiple partners

▪ Increase in number of RFQs received from various global biotech

▪ Shilpa’s First ADC biosimilar is expected to enter human studies in FY27

▪ Dual-capability platform in both small molecules and biologics manufacturing provides global pharma partners with unmatched integration, simplifying their supply chain and development needs

▪ Novel MAB (oncology): Our development program is underway for a key asset with mAbTree, targeting clinical trials in late FY27

▪ Novel Live Biotherapeutic

Product (LBP) Development & manufacturing contract signed with Alveolus Bio. Initiated development activities

▪ Alveolus and mAbTree NBE

projects are expected to enter Phase 1 studies in FY27

▪ Albumin - Global Phase 3 clinical trial protocol submitted to CDSCO along with IMPD filing to EMEA for Global Phase 3 clinical trials targeted in 2HFY26

▪ Adalimumab: India market sees

growth, 24-month shelf life approved. Filing in progress in 15 RoW markets, with approvals expected in FY26. RoW approvals expected 2HFY26. EMA SA targeted in Q4FY26.

▪ Aflibercept: Ophthalmic biologic with a global market size of ~USD 5 bn1 . Entered Phase 3, targeting FY27 launch; Out-licensed to two partners in India and Russia, with active discussions in MENA region

▪ Nivolumab (USD 11 bn) 1, CTA filed and targeting Phase 1/3 human trial initiation in 2HFY26. European Scientific Advice targeted

▪ Pembrolizumab (USD 33 bn) 1 PCT

completed

▪ Daratumumab (USD 13 bn) 1 and Dupilumab (USD 21 bn) 1 cell line development is in-progress

▪ Trastuzumab (USD 3 bn) 1 process

development completed with scale up completed

Diversified portfolio – 1 Commercial, 2 NBEs, 6 in Pipeline including 1 ADC

1. Global Market share, Source: IQVIA – MAT-June 25

Why Recombinant Human Albumin ?

Predictable & assured supply – Product in yeast (Pichia pastoris) by fermentation

All raw materials used in the production are free from animal sources

High quality/Purity Meets Global standards

Freedom from potential contamination sources – inherently free from HIV, HBV, HCV, Prion contamination

Best in class productivity – makes the product competitive in comparison to plasma Albumin

Recombinant Human Albumin – High growth opportunity

Key highlights

Shilpa’s novel rHA (Recombinant Human Albumin)

Regulatory filing status

Addressing the global unmet need

IP Positioning

▪ Entered into a strategic partnership with Orion Corporation for commercialization in Europe region for therapeutic use ▪ Under this agreement, Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa’s

Recombinant Human Albumin for therapeutic use in Europe

▪ Shilpa is entitled to receive from Orion certain development and regulatory milestone payments ▪ Shilpa has been investing in the development of this novel product for about 8 years and has also set-up a large-scale

fermentation facility for manufacturing

▪ India – Initiating Phase 3 trials in FY26

▪ EU – Initiating Phase 3 trials in FY26

▪ US – Pre IND to be filed 2HFY26

▪ Non-Therapeutic - Samples shared with few clients in US

▪ Shilpa has developed recombinant Human Albumin (rHA)

▪ Targets to fulfil growing demand of human serum albumin

▪ All the raw materials used in manufacturing are animal origin free (AOF)

▪ Shilpa’s Recombinant Human Albumin production technology is covered by patents in developed markets viz. US &

Europe

CDMO Business

Covering full spectrum of CDMO technologies

Shilpa Medicare

Peer 1

Peer 2

Peer 3

Global Peer 1

Global Peer 2

Global Peer 3

Very strong capability

Strong capability

Developing capability

Negligible capability

Indian CDMOs

Global CDMOs

Specialized technologies

Small molecule

Peptide

Monoclonal Antibodies and Recombinant technology

Antibody – Drug conjugates

Fermentation

Offerings

Development

Manufacturing

▪ Early phase to late phase from AI/ML led discovery (target to hit, hit to lead and lead to NCE) to custom synthesis, scale up and clinical materials (for advanced intermediates,

RSMs

▪ “Clone-to-vial" capabilities makes us a preferred one-stop outsourcing partner, securing strong market position ▪ Leveraging expertise to offer interconnected tech platform for various fast growing opportunities in the areas of fermentation, Antibody-Drug Conjugates (ADCs), and GLP-1 ▪ Leveraging exquisite strengths in complex chemistry across pharma and specialty chemicals. Integrated CMC approach for delivering drug substance and drug product to pharma

customers

▪ One of the very few CDMO companies from India having integrated CDMO Biologics offerings ▪ One of the very few CDMO companies from India having One Stop Solutions for Integrated CDMO offerings in ADCs

Robust business model encompassing various stages

Value chain stages

Development & Clinical supplies

Late stage development & Commercial Manufacturing

Phases

Pre-Clinical Development

Clinical development & Supplies

Registration

Commercial Manufacturing

▪ Drug metabolism, pharmacokinetics (DMPK)

▪ Phase 3 clinical trials

Key steps

▪ Toxicology studies (Safety studies)

▪ Manufacturing clinical supplies

▪ Phase 1 and 2 clinical trails

▪ Drug filing with regulatory authorities

▪ Drug substance manufacturing (RSM, intermediates, APIs) and formulation

Number of projects

25+

Comprehensive CDMO Development

Long term manufacturing and supply agreement with SML.

SML’s milestone income spans over various stages viz. filing, approval and launch of the product

Unicycive Therapeutics Inc’s Oxylanthanum Carbonate (OLC) is a Potential best-in-class product being developed under FDA’s 505(b)(2) regulatory pathway for the treatment of hyperphosphatemia

NDA accepted by the US FDA

Product Profile1 ▪ Potential best-in-class product for the treatment of Hyperphosphatemia ▪ Advantages:

(1) Potency: Shares high phosphate binding capacity of lanthanum

(2) Pill Burden: Smaller and fewer pills

(3) Palatability: swallowed whole with water and not chewed

1. Source: Unicycive Presentation

Building back-end to develop & manufacture both API & Formulation

▪ A comprehensive CDMO contract for both API and formulation

development – a One-stop-Solution

▪ Unicycive received a Complete Response Letter (CRL) from the FDA,

citing deficiencies related to a third-party drug product manufacturer (unaffiliated with Shilpa Group)

▪ In response, the Company has proactively qualified an alternative supplier that has already successfully produced OLC drug product batches. This vendor will support resolving the CMC issues outlined in the CRL

▪ Expect commercialization in FY27

Outlook

FDF

CDMO

API

Biologics

NDA – Pemetrexed, Bortezomib and Ondansetron ER

One NCE project to commercialize in FY26

Hybrid – Nilotinib (limited competition), Axitinib & Rotigotine

One NCE projects to commercialize in FY27

Multiple complex API launches, growth in Specialty portfolio, coupled with capacity expansion for existing key products to drive API growth

Strong Biosimilar pipeline with various large assets completing clinical trails, coupled with niche CDMO Biologic offerings to drive Biosimilar revenue growth in significant manner

NorUDCA – First-In-Class for NAFLD in India, followed by launches in RoW

Two NBE projects expected to enter human studies in FY27

Recombinant Albumin

Licensing income

Impending Operating Leverage

Margin Improvement

Phase 3 trials for India and Europe to start in FY26

Strategic tie up with Orion Corporation for therapeutic use

Non – Therapeutic usage is being explored

Various assets where licensing income was received are moving towards commercial long term supply agreements

Substantial portion of current gross block remains under utilized having spread across high margin divisions viz. Biosimilar, CDMO and NDDS

Improved utilization is likely to drive meaningful improvement in revenue and EBITDA margins

Manufacturing Capabilities – API & Biocare

API Unit I - Raichur

API Unit II - Raichur

Biocare - Kadechur

Capabilities

Onco, Non-Onco NCE, APIs, Peptide and Polymers, Manufacturing proficiencies at gram- to-multi kilo and ton scales

Capacities

• 11 mfg blocks (4 onco and 7 non-onco) • Total reactor capacity of 650 KL

• Manufacturing and R&D Centre • Small molecule development, Linker, GalNAc Chemistry, Asymmetric synthesis, Chiral Chemistry, Peptides, Polymers, Enzymes, Purification, RP-separations CDMO services

• 10 mfg blocks (5 onco and 5 non onco) • Total reactor capacity of 510 KL

Major Regulatory Accreditation

• US FDA • EU GMP • ANVISA • COFEPRIS • TGA

• PMDA • Russian – GMP • WHO-GMP • KFDA • TPD

• US FDA • EU GMP • ANVISA • COFEPRIS • TGA

• PMDA • Russian – GMP • TDP • WHO-GMP • KFDA

• Fully automated integrated facility with DCS

control system

• Filtration system for protein separation

• 200KL+ Fermentation capacity • Capacities ranging from 5 KL to 50 KL for

product vessels and 5 KL to 15 KL for buffer vessels

• Audit ready

Manufacturing Capabilities – Formulations & Biologics

Formulations - Jadcherla

Formulations - Bangalore

Biologics - Dharwad

Capabilities

OSD tablets and capsules; Injectables – dry powder and liquid lyophilization

Fully automated facility for Transdermal patches and Oral Thin Films

Capacities

Injectable - ~3mn Liquid Vials Lyophilized - ~2mn Vials OSD – 25mn Tablets Capsules – 4mn Hard Capsules

ODF - ~50mn Units TDF - ~30mn Units

End-to-end services, from development to commercial manufacturing of microbial & mammalian-based drug substance and drug products. Having expertise in complex technologies viz. ADC, peptides and conjugated proteins

Upstream – 4,000LX2 Microbial Suite – SS 1,000LX2 PFS – 80 units/min

Major Regulatory Accreditation

EU GMP, ANVISA, TGA, WHO-GMP, SHAPRA, SFDA, Health Canada, GHC

US FDA, WHO-GMP, UK-MHRA, EU GMP, TGA, SFDA

• EU GMP, DSIR Approved facility

Financials

Profit & Loss Consolidated

Particulars (INR cr)

2QFY26

2QFY25

YoY

1QFY26

QoQ

1HFY26

1HFY25

Revenues

Gross Profit

Gross Margin %

Employee Cost

Other Expenses

EBITDA

EBITDA Margin %

Finance Cost

Depreciation

PBT

PAT

372

266

72%

110

30%

349

227

65%

26%

17%

22%

21%

-38%

73%

144%

328

248

76%

30%

13%

12%

-16%

28%

-6%

700

514

74%

165

142

208

30%

114

651

436

67%

148

114

174

27%

All numbers are rounded off to nearest one

YoY

18%

11%

25%

20%

-31%

75%

184%

Balance Sheet Consolidated

Particulars (INR cr)

Fixed Assets

▪

Tangible Assets

Intangible Assets

Capital WIP

▪

Tangible Assets

Intangible Assets

Other Non-current Assets

Net Working Capital

▪

Current Assets

Cash and cash equivalents

Current Liabilities

Total Assets ( Net)

▪

Equity

Borrowings (Current & Non-current)

▪ Other Non-Current Liabilities

Total Liabilities

All numbers are rounded off to nearest one

30-Sept-25

1,414

1,192

222

920

534

386

102

681

1,026

-367

3,117

2,439

591

3,117

31-Mar-25

1,418

1,212

30-Sept-24

1,363

1,168

205

822

463

359

666

957

-320

2,978

2,364

586

2,978

195

785

455

330

110

589

840

-270

2,847

2,319

489

2,847

Earnings call Details

Shilpa Medicare 2QFY26 Results Conference Call to be held November 17, 2025, Monday at 11:00 IST

Details of Earnings Conference Call

Universal Access

+91 22 6280 1130 +91 22 7115 8031

The number listed above is universally accessible from all networks and all countries

International Toll-Free Numbers

USA UK Singapore Hong Kong

18667462133 08081011573 8001012045 800964448

DiamondPass

Link

Click here to join with DiamondPass

(No Wait Time)

THANK YOU!

Shilpa Medicare Limited

Monish Shah

+91 2249748754

monish.shah@vbshilpa.com

← All Transcripts SHILPAMED Stock Page →

Shilpa Medicare Limited has informed the Exchange about Investor Presentation

Market Movers